Ośrodek Rozwoju Nowych Technologiisp. z o.o.
Research and experimental development on biotechnology
KRS: NIP: REGON:
Overview
Status
Active
Registry date
2016-03-22
Share capital
5,000.00 PLN
Registered address
ul. Krzywa 31, 24-100 Gołąb, Poland
Financials
Revenue history (in k)
Filing timeliness
2 of 6 financial statements were filed late (the longest delay 96 days for 2025).
- 202519/10/2026
- 202415/07/2025
- 202315/07/2024
- 202228/06/2023
- 202127/09/2022
- 202012/10/2021
Filed on timeDelayFiling deadline
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Industry
Authorized Representatives
Dariusz Osiak – President of the Management Board
Paulina Plaminiak – Vice President of the Management Board
Manner of representation
Each member of the company's management board is independently authorized to make declarations of will on behalf of the company.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Dariusz Osiakage 61 | 25 | $675.31 | 50% |
Paulina Plaminiakage 37 | 25 | $675.31 | 50% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2017-02-01.
24 1020 3219 0000 9902 0131 3329
Debt
No entries in the National Debtors Register (KRZ).
Public aid
6 public aid cases recorded, with a total value of $8,907.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jan 7, 2022 | De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier) | –– | Kancelaria Prawna Filipek & Kamiński S.K.A. | |
| Sep 20, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | –– | Prezes Zakładu Ubezpieczeń Społecznych | |
| Jun 20, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | –– | Prezes Zakładu Ubezpieczeń Społecznych |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2016-09-01 | Centre for the development of new technologies | $176.9K$176,921 | Regional Operational Programme of the Lubelskie Voivodeship for 2014-2020 |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Scanomesp. z o.o. | $12,895.57 | scanome.com | ||
| Detoxedsp. z o.o. | $11,972.37 | detoxed.pl | ||
| ArthecS.A. | $10,911.16 | arthec.eu | ||
| Vitagenumsp. z o.o. | $9,376.94 | vitagenum.pl | ||
| 4cell TherapiesS.A. | $9,123.06 | 4celltherapies.com | ||
| Mamygenysp. z o.o. | $8,232.62 | mamygeny.com | ||
| Innosilsp. z o.o. | $7,984.08 | innosil.pl | ||
| Oncotherics PolandS.A. | $7,565.33 | oncotherics.com | ||
| GenomtecS.A. | $5,273.73 | genomtec.com | ||
| Fusiomicasp. z o.o. | $5,263.98 | fusiomica.com |
FAQ
The main business activity of Ośrodek Rozwoju Nowych Technologii focuses on research and experimental development on biotechnology.
The company was registered in the Polish National Court Register (KRS) on March 22, 2016.
The headquarters is located at: ul. Krzywa 31, 24-100 Gołąb.
The share capital of the company is PLN 5,000 (approx. $1,351).
The latest available financial statement covers the period from January 1, 2025 to December 31, 2025.
The company reported a revenue of USD -209 in 2025, which is a decrease of 102.4% compared to 2024.
No, in 2025 the company was not profitable, reporting a net loss of USD 33,749. For comparison, in 2024 the loss was USD 26,068, meaning the company increased its loss by 29.2%.
The largest operating cost category falls under employee remuneration. This category amounted to USD 13,969 in 2025, representing 42% of all operating expenses.
Last updated: 2026-10-19